Tina Wong-Russell

Tina Wong-Russell

Tina is a consultant and executive coach, working with clients in both the public and private sectors. She brings a global perspective from years of working in Europe, Latin and North America, and especially Asia. Her consulting engagements have included strategies and programs in organizational development and talent management initiatives, such as leadership development, performance & talent management, succession planning and learning & development. Tina’s experience spans multiple industries and multinational organizations, with emphasis in life sciences and technology ranging from Fortune 500 companies to start-ups. She has also had multi-year consulting engagements with Federal Government Agencies, including Homeland Security and NASA. She is a board member of the National Association of Asian American Professionals (NAAAP) in Boston and is fluent in Chinese.

Education:

Boston University (MBA)
Boston University (BS in Communications)

Thyagi Thyagarajan

Thyagi, a 38-year veteran of GlaxoSmithKline (GSK), is actively involved as an advisor/mentor to a Singapore-based med-tech start-up and a venture-funded healthcare company in India. He has been an independent non-executive director on boards of global companies such as Tata Consultancy Services Ltd, Varian Medical Systems, and the Murugappa Group of Companies, a leading family-owned conglomerate in South India.

Thyagi’s tenure with GSK included senior executive roles as Marketing Consultant in Spain and Europe, Marketing Director of Middle East, Africa and Eastern Europe, and Managing Director of GSK India, culminating with his role as Regional Director and Senior Vice President of GSK Asia Pacific. In this capacity, he was a member of the International Management Team of GSK. Thyagi was also chairman of PhRMA (Pharmaceutical Research Manufacturers of America) for Asia from 2005 to 2008, leading the industry’s advocacy with governments in the region. Before his retirement from GSK in 2008, Thyagi served on the Board of International Enterprise (I.E.) Singapore, a statutory board of the Government of Singapore responsible for promoting Singapore’s overseas trade, and as vice-chairman and non-executive director on the board of GlaxoSmithKline Ltd in India, a publicly listed company.

Having worked in both developed and emerging markets, Thyagi has a unique east-west perspective and an in-depth knowledge of Asia and Asian markets, combined with expertise in running significant business operations for a global corporation in Asia. Thyagi is fluent in Hindi and Tamil.

Education:

Indian Institute of Management, Ahmedabad (MBA)
Indian Institute of Technology (BS in Electrical Engineering)

Victor Shi, PhD

Victor is chairman of careLYFE and General Partner of venture capital firm Serica Partners. He previously served as CEO of Adicon Clinical Laboratories, a leading independent clinical laboratory in China, and President Asia Pacific of QIAGEN, a NASDAQ- and Frankfurt-listed leading company focused on in vitro diagnostics and life science research tools. Victor held senior positions at Aura Partners, Bridge Pharmaceuticals, Genospectra and Pappas Ventures. He was a faculty member at the National University of Singapore School of Medicine and a cancer research scientist at Merck & Co.

Victor is a Founding Director of BayHelix Group, a global association of Chinese life science business executives, and was elected Chairman from 2018 to 2019. He also serves on the Hong Kong Stock Exchange Biotech Advisory Committee.

Education:

University of Rochester (PhD)
University of Rochester (MS)
University of Science and Technology of China (BS)

Stanley Lau

Stanley is CEO of TaiLai Biosciences, a Chinese biotechnology company providing a new generation of biopsy products and services based on its proprietary biomultiomics technology. With over 40 years of business and healthcare experience, Stanley has served in a variety of senior roles in China and internationally with organizations including MSD, Baxter, Schering-Plough, China Biologic Products and Amsino Medical Group. He currently serves as Non-Executive Chairman of the Board of Gland Pharma and as an independent director of Solasia Pharma K.K.

Education:

University of London (BPharm)

Phil Kohn

Phil is a Founding Partner of Myndful Venture Partners, a consultancy focused on digital strategies for new media and emerging technology companies. Phil founded Candence Translate in 2014, a 500 Startups-backed venture started in Beijing and currently providing top-tier language services to the global business and investment community. His prior experience includes corporate finance and international busines development roles at Scientific Games (NASDAQ: SGMS), a multinational lottery and gaming company, and investment banking as part of Credit Suisse’s media and telecom group. Phil is fluent in Mandarin.

Education:

University of Michigan – Ross School of Business (BS in Business Administration)
Tsinghua University, Beijing (Inter-University Program in Mandarin)

Miranda Gottlieb

Miranda is Vice President of Marketing for Curative, a leading COVID-19 diagnostic and vaccine delivery start-up in the United States. Miranda heads the organization’s product marketing and strategic communications serving over 20 million patients and 7 thousand employees in 26 states.

Miranda began her career with the State of Florida’s Office of Substance Abuse and Mental Health focusing on public health communication and prevention. She later attended graduate studies at Tsinghua University as a Schwarzman Scholar in Beijing, China. Following graduation, Miranda joined Johnson & Johnson’s enterprise government affairs team where she specialized in Chinese health policy. She then led the Innovation Activation team for Johnson & Johnson Innovation | JLABS @ Shanghai, a start-up incubator with over 40 portfolio companies across the Asia Pacific region.

Education:

University of Tennessee (BA in Political Science and Hispanic Studies)
Tsinghua University, Beijing (MA in Global Affairs)

Patrick Daly

Patrick joined Pappas Capital in 2019 as an Executive-in-Residence.  He is a seasoned global executive with a proven track record of entrepreneurship, building winning cultures and growing companies small and large. He has a unique ability to create, shape and implement strategic agendas, and motivate diverse teams to achieve results beyond what was expected. Prior to joining Pappas Capital, Patrick founded Cohera Medical, Inc. and shepherded it through commercialization while successfully raising multiple rounds of financing, including from KKR.  The company was previously named the Pittsburgh Technology Counsel Company of the Year and Patrick was honored as CEO of the Year. He was also a three-time Ernst and Young Entrepreneur of the Year finalist.

Patrick was recently the Chairman of the Advanced Medical Technology Association (AdvaMed) Accel Board, the division within AdvaMed dedicated to the needs of smaller medical technology manufacturers. He enjoyed a successful tenure on the Executive Board of AdvaMed and has nurtured and developed strong relationships with the Fortune 500 Med Tech CEOs. Earlier in his career, Patrick spent over 15 years at Johnson & Johnson (J&J) in a variety of cross-functional and international assignments in the U.S. and Asia Pacific. His work using six-sigma to improve the Key Opinion Leaders experience garnered the J&J Corporate Standards of Leadership Award. He has frequently been invited to speak on entrepreneurship and company development at the MBA programs at Carnegie Mellon and the University of Pittsburgh Heinz School of Business.

Patrick has a passion and commitment to America’s military. Along with his classmates from West Point, he founded The Johnny Mac Soldiers Fund, which has raised over $22 million in college scholarships for Gold Star children.

Education:

United States Military Academy at West Point (BS in Foreign Area Studies)

Karen LeVert

Karen has a long history of further developing early stage technologies from university research labs and launching them into the commercial marketplace. These commercialization efforts led to spin-off companies in optoelectronics, medical devices, and agriculture via Southeast TechInventures, Inc. (STI) and Ag TechInventures, LLC (AgTI) – innovation labs she co-founded. Karen’s business experience encompasses both corporate and entrepreneurial worlds with over twenty-five years of successful leadership experience in executive management, start-ups, and technology commercialization. Karen started her career at a Fortune-500 insurance company holding positions of increasing responsibility from computer programmer, to controller, to general manager of a 500-person Property & Casualty service center. Before founding the innovation labs, her first entrepreneurial venture was launching a franchise bioremediation company that she later sold. Her next entrepreneurial venture was co-founding a Silicon Valley based software company. Along with her professional duties Karen serves as a board member for the North Carolina Biotechnology Center, the Economic Development Partnership of North Carolina, the North Carolina School of Science and Math, the NC IDEA Foundation, and LCBA Life Insurance Company.

Education:
University of Dayton (MBA)
Eastern Michigan University (BBA Information Technology)

Featured Image

Peter Young

Peter is an experienced life science industry consultant and leads the firm’s initiatives in translational medicine. He is the Program Manager for the Wake Forest Technology Development Program and also provides business development and due diligence support to the firm's venture funds and portfolio companies. Peter joined Pappas Capital in 2012, serving initially as an Executive-in-Residence and currently as a Venture Partner.

Peter has 40 years of experience in the pharmaceutical and biotechnology industry, spanning all areas of the business from sales representative to country-level general manager and CEO; and companies ranging from multinationals like Abbott and Glaxo to start-up biotechnology companies. As Vice President and Therapy Area Head at Glaxo Wellcome in the mid-1990s, he led the global introduction of combination HIV therapy that revolutionized HIV treatment and quintupled Glaxo’s global HIV portfolio sales, while keying industry leadership on global treatment access. Peter has since served as CEO of two private start-up enterprises, a viral vector vaccine company that raised over $80 million in NIH HIV and biodefense vaccine grants, and a specialty pharmaceutical company he led to an exit via a strategic transaction.

Peter currently serves on the Oversight Committee for the University of Miami Wallace H. Coulter Center for Translational Research, and is a member of the Long Island Bioscience Hub External Review Board. He is also an Executive-in-Residence at Cold Spring Harbor Laboratory and the Stony Brook University Center for Biotechnology, and also serves as a Mentor-in-Residence at Rutgers University. Peter was a past member of the BIO board, past Chairman of the North Carolina Biosciences Organization (NCBIO), and was a director of Memory Pharmaceuticals from 2004 until its sale to Roche in 2009. He has lived and worked in the US, Greece, the Middle East, Puerto Rico, New Zealand and London.

Education:

Indiana University (BA, History)
IU Kelley School of Business (MBA)

Featured Image

Barry Myers, MD, PhD

Barry joined Pappas Capital in 2004 as an Executive-in-Residence. His experience and background enable him to bring a deep knowledge of medical devices, business and clinical practice to the table.

Barry has been a member of the Duke University faculty for 29 years, currently serving as Director of Innovation in the Duke Clinical Translational Science Institute, and as the Coulter Program Director where he manages seed funding to help commercialize Duke faculty innovation. He is also a professor of Biomedical Engineering, with appointments in Surgery and Business Administration. Barry has considerable experience in both business and academic leadership, having served as Managing Director of the Duke Office of Licensing and Ventures. He is recognized as a world leader in injury research and product safety, with over 100 publications. In addition to his roles at Pappas Ventures and Duke, Barry maintains an active consulting practice, advising clients including the NFL, NASCAR and most major automotive manufacturers and US federal organizations concerned with product safety. Barry previously served as a board observer for Pappas Ventures III portfolio companies Gentis and TYRX.

Education:

University of Toronto (BS in Mechanical Engineering)
Duke University (MD)
Duke University (PhD in Biomedical Engineering)
Duke University (MBA)